ProCE Banner Series

Critical Actions in Emergency Medicine: Timely Diagnosis and Treatment of CAR-T and Bispecific Antibody–Related AEs in Multiple Myeloma

Register now for this live CME/CNE/CPE/AAPA-certified 1-hour workshop to gain expert guidance on the adoption of BCMA-directed CAR T-cell and bispecific T-cell engaging therapies into multiple myeloma and how emergency medicine providers can screen and manage care of patients on these agents that present to the emergency department.

  AAPA
  | ACPE
  | AMA
  | ANCC
Who Should Attend

This program is intended for emergency medicine physicians, nurses, pharmacists, advanced practice providers in emergency medicine, and emergency medicine health professionals involved in the screening and management of patients with multiple myeloma who present to the emergency department for care.

All Events

Upcoming Events

June

26

2024

Critical Actions in Emergency Medicine: Timely Diagnosis and Treatment of CAR-T and Bispecific Antibody–Related AEs in Multiple Myeloma [Open Registration]

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

CCO Simulcast | Host Group MD, Baltimore, Maryland

Past Events

January

22

2024

Critical Actions in Emergency Medicine: Timely Diagnosis and Treatment of CAR-T and Bispecific Antibody–Related AEs in Multiple Myeloma

4:30 PM - 5:30 PM Alaska Standard Time Zone (AK)

Virtual

Private Event, Anchorage, Alaska

April

18

2024

Critical Actions in Emergency Medicine: Timely Diagnosis and Treatment of CAR-T and Bispecific Antibody–Related AEs in Multiple Myeloma [Open Registration]

11:00 AM - 12:00 PM Central Time (CT)

Virtual

CCO Simulcast | Host Group AL, Birmingham, Alabama

May

21

2024

Critical Actions in Emergency Medicine: Timely Diagnosis and Treatment of CAR-T and Bispecific Antibody–Related AEs in Multiple Myeloma [Open Registration]

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

CCO Simulcast | Host Group MI, Royal Oak, Michigan

Faculty

ProCE Banner Faculty
Doris K. Hansen, MD

Assistant Member
Department of Blood and Marrow Transplant and Cellular Immunotherapy
Moffitt Cancer Center
Assistant Professor
Department of Oncologic Science
Morsani College of Medicine
University of South Florida
Tampa, Florida

ProCE Banner Faculty
Shonali Midha, MD

Jerome Lipper Multiple Myeloma Center
Department of Medical Oncology
Instructor, Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

ProCE Banner Faculty
Ajay K. Nooka, MD, MPH, FACP

Professor
Department of Hematology and Medical Oncology
Associate Director of Clinical Research, Winship Cancer Institute
Medical Director, Winship Data and Technology Applications Share Resource
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

ProCE Banner Faculty
Krina Patel, MD, MSc

Associate Professor, Department of Lymphoma-Myeloma, Division of Cancer Medicine
Co-Director, Lymphoma Myeloma Cellular Therapy Program
Associate Program Director, MDACC Hematology Oncology Fellowship Program
The University of Texas MD Anderson Cancer Center
Houston, Texas

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with Multiple Myeloma

Target Audience
This program is intended for emergency medicine physicians, nurses, pharmacists, advanced practice providers in emergency medicine, and emergency medicine health professionals involved in the screening and management of patients with multiple myeloma who present to the emergency department for care.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Distinguish the different mechanisms of action for the BCMA-directed agents and their impact on T-cell function in patients with heavily pretreated relapsed or refractory multiple myeloma
  • Compare and contrast emerging safety and efficacy data on CAR T-cell therapies and bispecific T-cell engager antibodies for the treatment of patients with heavily pretreated relapsed or refractory multiple myeloma
  • Effectively identify and employ clinical and pharmacologic treatments for adverse events associated with the use of CAR T-cell therapy and bispecific T-cell engager antibodies approved for heavily pretreated relapsed or refractory multiple myeloma

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-24-029-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

LogoDescription automatically generated

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by an education grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.